BupPractice

DATA 2000 Qualifying Buprenorphine Training

Home › Training › Waiver Training for NPs & PAs Part 2: 16 hours SBIRT, Opioids, Pain, and Risk Reduction
Price: Included with Part 1

Waiver Training for NPs & PAs Part 2: 16 hours SBIRT, Opioids, Pain, and Risk Reduction

Goal: To provide a core training to Nurse Practitioners and Physician Assistants who meet the requirement of the federal CARA 2016 law (which includes an 24 hour training experience), in order to increase the number of providers who are knowledgeable about and qualified to prescribe buprenorphine to their patients with opioid use disorder.
  or  Register

This activity is designed to change: Competence, Performance. 16 hr(s)

Overview

Goal: This activity aims to:

  1. Train health care providers to apply the clinical skills of screening, brief intervention, and referral to treatment (SBIRT) with patients having substance use problems. Additionally, to train providers in basic motivational interviewing techniques to motivate people having substance use to change behaviors contributing to substance use problems. To adapt these skills according to the substance involved, severity of the substance use problem, and other individual patient needs. (SBIRT Goal – 5 hrs)
  2. Enhance clinical skills of health professionals in treating pain safely and effectively while reducing the risk of addiction/substance abuse/misuse and overdose in patients being treated for pain as well as recognizing and addressing these problems in patients. Specifically:
    • To prepare healthcare professionals who prescribe opioids to fully assess patients before prescribing them, prescribe all opioids carefully and safely, and monitor patients for early detection and prevention of serious adverse events. Further, to become familiar with general and specific drug information on ER/LA opioid analgesics, such as instructions for use, special precautions, adverse effects/side effects, drug interactions, opioid tolerance, the risk of overdose, conversion methods, product safety, dosing, and effect of tolerance.
    • To apply clinical skills with respect to reducing the risk of addiction/misuse of opioids and other prescribed controlled substances, recognizing and addressing drug-related aberrant behavior, urine drug testing and other ongoing monitoring of patients on chronic opioid therapy, coordinating care of these patients with a multidisciplinary team, and assuring adequate pain management in patients with substance use disorders without further contributing to patient substance use problems.

    (Opioids, Pain, Risk Reduction Goal – 11 hrs)

Professional Practice Gaps – SBIRT
Professional Practice Gaps – Opioids, Pain, Risk Reduction

Educational Objectives:

After completing this activity participants will be able to:

SBIRT
  • Select and utilize tobacco, alcohol, and drug use screening tools with patients.
  • Perform brief interventions for tobacco and substance use problems with patients.
  • To use basic motivational interviewing techniques to motivate patients having substance use problems to change behaviors in order to improve health.
  • Refer patients to the appropriate type of substance abuse treatment center and/or specialist
  • Follow-up with and reassess patients who receive treatment for substance abuse or tobacco use
  • Apply the SBIRT approach to substance use problems at a comprehensive and integrated level by individualizing screening, brief interventions, and referral for different patients.
Opioids, Pain, Risk Reduction
  • Review basic pain history, assessment, and diagnosis
  • Describe the main pharmacological and non-pharmacological categories of pain treatments used as first-line treatment for different categories of pain and common pain conditions
  • Collaborate with colleagues in a multi-dimensional/multidisciplinary approach to pain management with a medical “home”
  • Recognize when opioid therapy is indicated based on pain severity, functioning, and risk of addiction or abuse, and potential harm from side effects
  • Develop an opioid medication treatment plan that minimizes risk of addiction, misuse, overdose, and side effects

Modules in this Training Activity

SBIRT
  • SBIRT: Brief and Effective Screening for Hazardous Substance Use
  • SBIRT: Brief Intervention and Other Treatments
  • SBIRT: Referral to Treatment & Follow-up Care
  • SBIRT: In Practice
  • Motivational Interviewing for Primary Care
Opioid Risk
  • Assessing Pain
  • Treatment of Pain
  • Opioids and Pain: Assessment and Treatment Planning Prior to Prescribing (ER/LA Opioids)
  • Opioids and Pain: Understanding ER/LA Opioids
  • Opioids and Pain: Weighing Risks and Benefits (ER/LA Opioids)
  • Opioids and Pain: Initiating, Monitoring, and Terminating Opioid Treatment (ER/LA Opioids)
  • Opioids and Pain: Identifying, Assessing and Responding to an Aberrant Behavior
  • Expanded Skills: Minimizing Opioid Diversion and Overdose Risk
  • Expanded Skills: The High Risk Patient and Opioids
  • Expanded Skills: Coordinating Pain Treatment with Colleagues
  • Cases to Assess Understanding – Barbara and Olivia

Training Activity References – SBIRT
Training Activity References – Opioids, Pain, Risk Reduction

Audience and Accreditation

Audience: Health care professional clinical level students, interns, and residents

Type Est. Time Released Expires
FAPA 16 hr(s) 4/16/18 4/15/21
DCBN 16 hr(s) 4/16/18 4/15/21

Accreditation Statement: Clinical Tools, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

FAPA Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 16 hour(s) of FAPA credit. Providers and other health professionals should claim only the credit commensurate with the extent of their participation in the activity.

DCBN Credit Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 16 hour(s) of DCBN credit. Clinical Tools, Inc. is an approved provider by the District of Columbia Board of Nursing and is registered with CE Broker, Provider #50-1942.

A letter of completion for up to 16 hour(s) is available for non-physicians.

A score of 70% on the post-test is required to complete the activity.

Participation Requirements

Funding
Initial development of this activity was supported by a grant from the National Institute on Drug Abuse (#1R44DA027245-01), a contract from the National Institute on Drug Abuse (#HHSN271200800012C), a contract from the National Institute on Drug Abuse (#HHSN271200900003C).

Authors

As an ACCME accredited provider of continuing medical education, Clinical Tools, Inc.requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest to the provider. The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Any conflicts of interest are resolved prior to the delivery of the educational activity to the learner. CTI does not permit individuals with financial conflicts of interest to participate in any stage of activity development.

T Bradley Tanner, MD (President, Clinical Tools, Inc.)
Disclosure: Has disclosed no relevant financial relationships. Dr. Tanner is the owner of Clinical Tools.
Karen Rossie, DDS, PhD (Research Scientist, Clinical Tools, Inc. )
Disclosure: Has disclosed no relevant financial relationships.

Reviewers

Steve Applegate, MEd, MEd (President, Applegate Consulting, )
Disclosure: Has disclosed no relevant financial relationships.

Opioids, Pain, Risk Reduction only:

Barbara St Marie, RN (RN, PhD candidate, University of Wisconsin)
Disclosure: Has disclosed no relevant financial relationships.
Teresa Holt, MD (Dr. Teresa Holt, MD, )
Disclosure: Has disclosed no relevant financial relationships.

Most Recent Reviews: SBIRT

CTI Content Review: Thu, 11/21/2018
CTI Editorial Review: Mon, 11/29/2018

Most Recent Reviews: Opioids, Pain, Risk Reduction

CTI Content Review: Thu, 1/5/2017
CTI Editorial Review: Mon, 1/9/2017